Study Designed to Assess the Safety, Tolerability and PK of PTI-808 in Healthy Volunteers and in Adults With Cystic Fibrosis

ClinicalTrials.gov ID: NCT03251092

Public ClinicalTrials.gov record NCT03251092. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PTI-808 in Healthy Adult Subjects and in Adults With Cystic Fibrosis

Study identification

NCT ID: NCT03251092
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Proteostasis Therapeutics, Inc.; Industry
Enrollment: 179 participants

Conditions and interventions

Conditions

Interventions

PTI-808 Drug
Placebo Drug
PTI-428 Drug
PTI-801 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 99 Years
Sex: All
Healthy volunteers: Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 16, 2017
Primary completion: Dec 22, 2019
Completion: Dec 22, 2019
Last update posted: Apr 21, 2020

2017 – 2019

United States locations

U.S. sites: 22
U.S. states: 20
U.S. cities: 21

Facility	City	State	ZIP	Site status
Banner University of Arizona Medical Center	Tucson	Arizona	85724	—
Stanford University Medical Center	Stanford	California	94305	—
National Jewish Health	Denver	Colorado	80206	—
Central Florida Pulmonary Group	Altamonte Springs	Florida	32803	—
Emory Children's Center	Atlanta	Georgia	30322	—
Northwestern Memorial Hospital	Chicago	Illinois	60611	—
Johns Hopkins University	Baltimore	Maryland	21287	—
Massachusetts General Hospital	Boston	Massachusetts	02114	—
Boston Children's Hospital	Boston	Massachusetts	02115	—
Michigan Medicine, University of Michigan	Ann Arbor	Michigan	48109	—
Harper University Hospital	Detroit	Michigan	48201	—
University of Minnesota	Minneapolis	Minnesota	55455	—
Children's Mercy	Kansas City	Missouri	64108	—
Billings Clinic	Billings	Montana	59101	—
University of Nebraska Medical Center	Omaha	Nebraska	68198	—
Dartmouth Hitchcock Medical Center	Lebanon	New Hampshire	03756	—
New York Medical College	Valhalla	New York	10595	—
University of North Carolina at Chapel Hill	Chapel Hill	North Carolina	27517	—
Children's Hospital of Philadelphia	Philadelphia	Pennsylvania	19104	—
Medical University of South Carolina	Charleston	South Carolina	29425	—
ICON Early Phase Services	San Antonio	Texas	78209	—
University of Utah	Salt Lake City	Utah	84132	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03251092, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 21, 2020 · Synced Jul 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03251092 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →